Status:
COMPLETED
Study of Sunobinop on Craving in Alcohol Use Disorder
Lead Sponsor:
Imbrium Therapeutics
Collaborating Sponsors:
Purdue Pharma LP
Conditions:
Alcohol Use Disorder
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the efficacy of sunobinop compared to placebo on alcohol craving in subjects with moderate to severe alcohol use disorder and these subjects are seeking treatm...
Eligibility Criteria
Inclusion
- Key Inclusion Criteria include:
- Male and female age ≥18 years.
- Diagnosis of moderate or severe alcohol use disorder.
- Currently seeking treatment for alcohol use disorder.
- Has 4 or more heavy drinking days (HDD) in each of the 4 weeks prior to baseline visit.
- Key Exclusion Criteria include:
- Subjects that meet current DSM-5 criteria for moderate or severe substance use disorder other than alcohol and nicotine.
- Other protocol-specific inclusion and exclusion criteria may apply.
Exclusion
Key Trial Info
Start Date :
January 28 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 14 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06545929
Start Date
January 28 2025
End Date
July 14 2025
Last Update
July 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ohio Clinical Trials
Columbus, Ohio, United States, 43212